Authors
Latest:
Promoting Drug Safety During BreastfeedingPharmacists can help women who breastfeed by identifying the safest drugs and dosage schedules to minimize exposure.
Latest:
Promoting Drug Safety During BreastfeedingPharmacists can help women who breastfeed by identifying the safest drugs and dosage schedules to minimize exposure.
Latest:
Health System Pharmacies Adopt Next-Generation TechIt's time for pharmacies to move into the future: Industry 4.0.
Latest:
Take a Cue from Your Queues!Queueing theory can help pharmacy managers control lines, wait times, and staffing issues.
Latest:
Promoting Drug Safety During BreastfeedingPharmacists can help women who breastfeed by identifying the safest drugs and dosage schedules to minimize exposure.
Latest:
What Pharmacists Need to Know About EpidiolexThe FDA recently approved cannabidiol oral solution to treat seizures.
Latest:
The Value of Board-Certified Psychiatric PharmacistsBeing recognized as a BCPP brings professional recognition and credibility as an expert in psychopharmacology and behavioral health matters.
Latest:
Pediatric Asthma: An Update for PharmacistsIn this month's peer-reviewed article, learn more about the illness affecting millions.
Latest:
Pediatric Asthma: An Update for PharmacistsIn this month's peer-reviewed article, learn more about the illness affecting millions.
Latest:
Pediatric Asthma: An Update for PharmacistsIn this month's peer-reviewed article, learn more about the illness affecting millions.
Latest:
The Regimen: Portrayal of Pharmacists in MediaJeffrey Bratberg, PharmD and Madi Hartling, a 2025 PharmD candidate, discuss the lack of pharmacists in medical shows and how pharmacists are typically portrayed negatively in media.
Latest:
Pharmacy Education: Foundation for Providing HealthAACP offers a rebuttal to a Drug Topics opinion article.
Latest:
3 compliance rules pharmacies must knowWith 2016 well underway, pharmacies of all sizes should review recent regulatory updates to ensure compliance with rules already in effect, and preparation for those to be implemented soon. Three, in particular, warrant a close look.
Latest:
GLP-1 No Longer on FDA’s Drug Shortage ListCompounding pharmacies help meet patient needs by formulating alternative versions in the face of drug shortages but are no longer allowed to compound them.
Latest:
FDA approves rolapitant to prevent chemotherapy-induced nausea and vomitingRolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
Latest:
Why You Should Become Board Certified in OncologyNew developments in cancer treatment require medication experts-here's how you can become that expert.
Latest:
NASH Drug Pipeline Shows PromiseAnalysts have forecasted the market for NASH drugs could reach $20 billion by 2025.
Latest:
OTC Progestin-Only Pill May Prevent Unintended PregnanciesAn over-the-counter (OTC) progestin only pill (POP) could potentially reduce the overall number of unintended pregnancies in the United States.
Latest:
Safinamide (Xadago): Approved as Add-On for Parkinson’sXadago has been approved as a supplementary medication for patients with Parkinson's disease who are having "off" episodes or whose disease is progressing.
Latest:
Ocrelizumab for Multiple SclerosisThe FDA has approved ocrelizumab for treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.
Latest:
Utilizing a PSAO's Strategic Alliance for Success During Open EnrollmentA high performing Pharmacy Services Administrative Organization (PSAO) actualizes its value proposition to its participating pharmacies by entering into viable strategic partnerships that add value to an independent pharmacy’s workflow processes.
Latest:
Ixazomib for multiple myelomaFDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
Latest:
Delafloxacin (Baxdela) for Acute Bacterial Skin InfectionsDelafloxacin (Baxdela) for treatment of acute bacterial skin and skin structure infections including cellulitis, wound infection, major cutaneous abscess, and burn infection.
Latest:
New combo therapy for chronic heart failureEntresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.
